Dr André Horatscheck
Dr André Horatscheck joined the MedChem group of H3D in January 2016 as Principal Scientific Officer and is a malaria project lead since April 2018.
He received his Diploma in 2006 from the Humboldt-Universität zu Berlin after completing his thesis in bioorganic synthesis with Prof O Seitz. He then joined the Medicinal Chemistry group of Prof J Rademann at the Leibniz-Institut für Molekulare Pharmakologie (FMP) in Berlin-Buch for his PhD thesis in 2007. During this time he worked on two main projects targeting protein tyrosine phosphatases and STAT5 in close collaboration with the institute's Screening Unit including synthesis and in vitro assays. After receiving his PhD (Dr rer nat) at the end of 2011 from the Freie Universität Berlin, he stayed on at the FMP as a Research Scientist in medicinal chemistry for the Helmholtz drug initiative that formed part of a drug development platform at the FMP collaborating closely with the Max-Delbrück Center for Molecular Medicine (MDC). In 2013, the platform became part of a newly founded MedChem group with Dr M Nazaré. During this time André led projects on the investigation of halogen-pi interactions, SAR studies and development of clathrin inhibitors and PI3K inhibitors, and prodrug approaches for clathrin inhibitors.